CEO

Mobile phone: 619-***-**** Email:

********@*****.***

CAREER SUMMARY: ?[pic]

My skills excel in developing life sciences companies, discovering and

patenting new medical technologies, building teams, developing strategic

plans with accurate timelines, cross-functional management coaching and

motivating personnel.

. Experienced in taking companies from private to public, developing

contracts, working with investor and public relations, human resources,

recruiting, maintaining and retaining talented personnel.

. Formed and provided leadership for project teams, complex problem

solving, developing objectives for projects and individuals and

maintaining accountability.

. Through the course of acquiring these skills I worked on many new and

challenging medical products.

. I developed and patented an anti-cancer, anti-infective and anti-

inflammatory sterol pharmaceutical platform.

. ?I collaborated in developing tissue specific adenoviral gene-therapy

vectors for cancer therapy.

. ?Led the first hematopoietic stem cell team to clinical proof-of concept

in multiple myeloma patients.

. ?I directed the first team that developed monoclonal antibodies and their

conjugates for human use including the bispecific antibody system.

. Filed BLA and ELA applications that were approved by the USFDA.

. My pharmacology training involved research in the metabolism and

disposition of new narcotic ?analgesic drug classes. I also isolated and

identified new drug classes from marine organisms.

. Through the course of my career I have worked with both SEC and USFDA

regulatory bodies and participated in numerous corporate governance

activities, such as the obligatory SEC filings and annual reports to the

shareholders. I also participated in board and shareholder meetings. I

worked closely with the finance groups to control orderly finances,

oversaw inventory control, corporate safety functions and participated as

a corporate safety officer.

. I am computer proficient in both the PC and MAC environments.

PROFESSIONAL HISTORY: [pic]

. Harbor Therapeutics, Inc., (formerly Hollis-Eden Pharmaceuticals)

Vice President R&D to Chief Executive Officer

. Prolinx, Inc., (acquired by Canberra)

Vice President, Therapeutics R&D

. Systemix, Inc., (acquired by Novartis)

Vice President, Therapeutics R&D

. Hybritech, Inc., (acquired by Eli Lilly & Co.)

Research Scientist Immunochemistry to Vice President Therapeutics R&D

(Hybritech) & Executive Director (Eli Lilly and Co.)

BUSINESS ACCOMPLISHMENTS: [pic]

. Harbor Therapeutics, partnered its portfolio of proprietary clinical

stage assets to Sinopharm Group. Achieved high visibility with major

"western" pharmaceutical companies.

. Prolinx, a small molecule chemical cross-linking company, was acquired by

Canberra.

. SyStemix, a stem cell company, sold (60%) to Sandoz, Ltd for ~600M. The

acquisition was completed with another ~400M.

. Hybritech, a monoclonal antibody company, was acquired by Eli Lilly and

Company for ~550M.

. Produced technology that became the foundation for a ~76M R&D

partnership.

. Transferred technology that became the foundation for IDEC

Pharmaceuticals.

R & D ACCOMPLISHMENTS: [pic]

. Established a sterol platform technology based on components of the human

metabalome.

. Developed pharmaceuticals that regulate chronic inflammatory disease,

innate immunity and malignant cell apoptosis.

. Developed a chemical cross-linking system that conferred tissue specific

tropism to adenovirus vectors.

. Directed programs on the human hematopoietic stem cell for bone marrow

transplantation. Developed seven monoclonal antibodies, two devices and

a process for stem cell isolation.

. Developed monoclonal antibody regimens for treatment of lymphomas, grafts

vs. host disease, aplastic anemia, melanoma, colon, breast, and prostate

cancer.

. Introduced 25 new biological drug candidates into clinical trials.

. Developed a new radioimmunotherapy dosimetry and cancer treatment.

. Developed a portfolio of "new generation" bispecific antibodies.

. Developed ELISA in vitro diagnostic assays for PSA, CEA, HCG, AFP and

IgE.

INTERNATIONAL EXPERIENCE: [pic]

. Clinical & Regulatory: South Africa, Netherlands, France, England, China,

Singapore, and Thailand. Pre-clinical: Netherlands, France, Italy,

Mexico, and China.

EDUCATION: [pic]

. Ph.D. Organic Chemistry, and B.S. Chemistry, University of California,

Davis

. Postdoctoral Equine Drug Metabolism, University of California, Davis

. Postdoctoral Marine Pharmacognosy, University of California, San Diego

o Business Administration, Executive Program for Scientists

and Engineers

PUBLICATION SYNOPSIS: [pic]

. PATENTS: United States; 23; Worldwide; >120

. JOURNAL ARTICLES: Peer Reviewed; 74

. PROFESSIONAL MEETINGS: Presentations and Abstracts; >86

. REGULATORY SUBMISSIONS: Investigational New Drug Applications; 32:

Product License Applications; 1: Establishment License Applications; 1

Contact this candidate